The Weekly Five | 9–15 November
Five studies worth your time this week, spanning brain metastases, Merkel cell carcinoma, nutritional support, breast radiotherapy and prostate SBRT.
The RadOncToday newsletter
Five selected radiation oncology studies, with key findings, context and limitations. Free in your inbox every Sunday.
Five studies worth your time this week, spanning brain metastases, Merkel cell carcinoma, nutritional support, breast radiotherapy and prostate SBRT.
Five studies worth your time this week, spanning lung SBRT, brain metastases, thoracic reirradiation, AI contouring and prostate dose escalation.
Five studies worth your time this week, spanning lung SBRT, prostate fractionation, feeding-tube strategies, plasmacytoma treatment and metastasis-directed therapy.
Five studies worth your time this week, spanning randomized breast radiotherapy, lung reirradiation, late brain toxicity, treatment sequencing and cardiac risk.
Five studies worth your time this week, spanning randomized breast radiotherapy, secondary malignancies, adjuvant treatment decisions, long-term toxicity and proton selection.
Five studies worth your time this week, spanning randomized evidence, long-term toxicity, salvage treatment, surveillance and particle-therapy QA.
Five randomized trials from ASTRO 2026, covering SCLC, prostate cancer, liver tumors and brain metastases—with key findings and limitations.